The tumor inhibition rate was decreased from 73.3% in control tumors to 45.5% in ABCA8-overexpressing tumors (Fig. 3F), suggesting that increased ABCA8 expression reduced the sensitivity of human PC cells to GEM therapy. This evidence concerns the gene ABCA8 and neoplasm.